Healthify and Berry Street Merge to Build AI-Powered Metabolic Health Platform for the US

The healthcare technology landscape is entering an interesting new phase, where artificial intelligence is increasingly being combined with clinical expertise rather than positioned as a replacement for it.

A new merger between Bengaluru-based healthtech company Healthify, formerly HealthifyMe, and US nutrition startup Berry Street is a notable example of this shift.

The companies have joined forces to build an advanced, insurance-covered AI metabolic health platform for the US market, bringing together Healthify’s AI capabilities with Berry Street’s clinical network and insurance infrastructure.

The combined company will be jointly led by Healthify founder Tushar Vashisht and Berry Street founder Noah Kotlove, who will serve as co-CEOs.

India’s Healthify and US-based Berry Street are combining AI-powered nutrition technology with clinical and insurance infrastructure as demand for metabolic healthcare continues to grow.

Combining AI with clinical care

Healthify has spent more than a decade building technology around nutrition, fitness and personalised health guidance. Its AI assistant, Ria, is designed to provide users with personalised nutrition and wellness support, complementing the company’s human coaching services.

The company says it has served more than 45 million users and has raised over $150 million from investors including Khosla Ventures, Blume Ventures and Chiratae Ventures.

Berry Street brings a different but highly complementary set of capabilities.

The US-based company operates a network of more than 2,000 clinics and provides insurance-covered metabolic and GLP-1 care. It also offers AI-powered nutrition coaching and meal tracking and says it has served more than 200,000 people through collaborations with platforms including Amazon and Walmart.

The merger therefore connects two important pieces of the healthcare puzzle.

Healthify brings the AI and consumer technology. Berry Street brings clinicians, healthcare delivery and insurance infrastructure. That combination could make it easier to deliver personalised metabolic care at scale.

Why GLP-1s matter

The merger comes at a time when GLP-1 medications are transforming the weight-management and metabolic-health market in the United States. Research cited by JPMorgan suggests that more than 30 million people in the US could be using GLP-1 medications by 2030. But medication alone does not address every aspect of metabolic health.

Patients may also require ongoing nutrition guidance, behavioural support, monitoring and access to qualified healthcare professionals. This creates an opportunity for platforms that can combine medication with continuous lifestyle and nutritional support.

That is precisely where the Healthify and Berry Street combination is positioned.

Instead of treating AI, nutrition and clinical care as separate services, the companies are attempting to bring them together within a single ecosystem.

An India-US healthtech combination

The merger is also notable because it connects an established Indian healthtech company with a rapidly growing US healthcare business.

In the United States, the combined company will operate under the Berry Street brand. In markets such as India, it will continue operating under the Healthify brand.

For Healthify, the deal represents another step in its expansion into the US market. The company had already begun expanding its American operations and introduced GLP-1-assisted programmes in India.

The strategic opportunity is significant. India offers Healthify a large consumer-health market and a substantial base of experience in delivering digital nutrition and fitness services at scale. The US, meanwhile, offers a much larger opportunity for insurance-linked healthcare delivery and increasingly sophisticated metabolic-care services.

The bigger healthcare trend

Perhaps the most interesting aspect of this merger is what it says about the future of AI in healthcare. The strongest applications of healthcare AI may not necessarily be those that attempt to replace doctors, dietitians or other professionals.

Instead, AI could become the layer that makes human expertise more accessible, continuous and scalable.

A patient might receive daily nutritional guidance from an AI system while still having access to qualified clinicians when medical intervention or expert advice is required.

That model combines the convenience of technology with the accountability and expertise of healthcare professionals.

Khosla Ventures founder Vinod Khosla, whose firm backed Healthify, described the combination as a way of pairing AI with a nationwide network of expert clinicians to expand access to metabolic care.

As GLP-1 adoption grows and healthcare systems search for more cost-effective ways to support patients over the long term, that model could become increasingly important. The Healthify-Berry Street merger is therefore about more than two healthtech companies joining forces.

It is a bet that the future of metabolic healthcare will be AI-enabled, clinician-supported and increasingly integrated with insurance and mainstream healthcare delivery.

And if the companies can execute on that vision, the combination could give an Indian-born healthtech platform a significantly larger role in one of the world's fastest-growing healthcare markets.